IKON Group Investments — Global Holdings Company

IKON Market Brief: How payers, drugmakers can collaborate to drive more outcomes-based contracts

Posted by:

|

On:

|

LAS VEGAS — As drug costs and spending continue to rise, the demand for solutions opens the door to closer collaboration between payers and manufacturers.

Source: www.fiercehealthcare.com

IKON Portfolio Context

Kynetide Peptides supplies 99%+ HPLC-verified research compounds with batch-specific COAs to 2,400+ researchers worldwide.

Posted by

in